<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of sudden cardiac arrest and sudden cardiac death</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of sudden cardiac arrest and sudden cardiac death</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of sudden cardiac arrest and sudden cardiac death</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip J Podrid, MD, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Olshansky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a>.)</p><p>The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation, and the event is called SCD if the patient dies [<a href="#rid1">1</a>]. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention.</p><p>The specific causes of SCA vary with the population studied and patient age  (<a class="graphic graphic_table graphicRef62184" href="/z/d/graphic/62184.html" rel="external">table 1</a>). SCA most commonly results from hemodynamic collapse due to primary ventricular fibrillation (VF) or polymorphic or monomorphic ventricular tachycardia (VT) degenerating into VF. This usually occurs in the setting of structural heart disease  (<a class="graphic graphic_waveform graphicRef118944" href="/z/d/graphic/118944.html" rel="external">waveform 1</a>) [<a href="#rid2">2</a>]. Less commonly, SCA may occur with bradycardia/asystole or pulseless electrical activity or electromechanical dissociation. (See  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a>.)</p><p>The outcome following SCA depends upon numerous factors including the underlying cause and the rapidity of resuscitation. (See  <a class="medical medical_review" href="/z/d/html/1028.html" rel="external">"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest"</a> and  <a class="medical medical_review" href="/z/d/html/973.html" rel="external">"Prognosis and outcomes following sudden cardiac arrest in adults"</a>.)</p><p>A patient is more likely to be resuscitated if they have ventricular tachycardia or VF rather than asystole or pulseless electrical activity. However, if the patient has a poorly tolerated cardiac rhythm, this may be the inevitable consequence of a dying heart. Thus, even early resuscitation may not be successful. </p><p>Most individuals suffering from SCA become unconscious within seconds to minutes as a result of insufficient cerebral blood flow. There are usually no premonitory symptoms. If symptoms are present, they are nonspecific and include chest discomfort, palpitations, shortness of breath, and weakness.</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Various criteria have been used to define SCA and SCD [<a href="#rid3">3</a>]. Difficulties in deriving a specific definition include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Events are witnessed in only one-third of cases, making the diagnosis difficult to establish in many instances [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is not possible to restrict the definition of SCA to documented cases of VT-VF or VF since the cardiac rhythm at clinical presentation is unknown in many cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of symptoms prior to SCA generally defines the suddenness of death. However, the duration of symptoms is unknown in approximately one-third of cases.</p><p></p><p>For these reasons, operational criteria for SCA and SCD have been proposed that do not rely upon the cardiac rhythm at the time of the event. The criteria focus on the out-of-hospital occurrence of a presumed sudden pulseless condition and the <strong>absence</strong> of evidence of a noncardiac condition (eg, central airway obstruction, intracranial hemorrhage, pulmonary embolism) as the cause of cardiac arrest.</p><p>The 2006 American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) to establish data standards for electrophysiology included definitions to guide documentation in research and clinical practice.</p><p>The following definitions of SCA and SCD were presented:</p><p>"[Sudden] cardiac arrest is the sudden cessation of cardiac activity so that the victim becomes unresponsive, with no normal breathing and no signs of circulation. If corrective measures are not taken rapidly, this condition progresses to sudden death. Cardiac arrest should be used to signify an event as described above, that is reversed, usually by CPR and/or defibrillation or cardioversion, or cardiac pacing. Sudden cardiac death should not be used to describe events that are not fatal."</p><p>Throughout this topic we will use the terms SCA and SCD as defined in the 2006 ACC/AHA/HRS document. However, many continue to use SCD to describe both fatal and nonfatal cardiac arrest.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Death certificate data suggest that SCD accounts for approximately 13 to 15 percent of the total mortality in the United States and other industrialized countries [<a href="#rid5">5,6</a>]. However, death certificate data may overestimate the prevalence of SCD [<a href="#rid7">7,8</a>]. In a prospective evaluation of deaths in one county in Oregon, SCD was implicated in 5.6 percent of annual mortality [<a href="#rid7">7</a>].</p><p>In absolute terms, the number of sudden cardiac deaths in the United States in 2019 was approximately 370,000 [<a href="#rid6">6</a>]. Despite advances in the treatment of heart disease, the outcome of patients experiencing SCA remains poor, although the prognosis varies significantly according to the initial rhythm and underlying cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/973.html" rel="external">"Prognosis and outcomes following sudden cardiac arrest in adults"</a>.)</p><p>The risk of SCA is dependent on several factors [<a href="#rid5">5,8,9</a>]. The incidence increases dramatically with age and underlying cardiovascular disease, as well as specific comorbidities (eg, diabetes)  (<a class="graphic graphic_figure graphicRef59028" href="/z/d/graphic/59028.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef52309" href="/z/d/graphic/52309.html" rel="external">figure 2</a>). In addition, men are two to three times more likely to experience SCA than women  (<a class="graphic graphic_figure graphicRef59028" href="/z/d/graphic/59028.html" rel="external">figure 1</a>). Among 161,808 postmenopausal women participating in the Women's Health Initiative who were followed for an average of 10.8 years, the rate of SCD was 2.4 per 10,000 women/year. Nearly half who had SCD did not have clinically recognized coronary heart disease [<a href="#rid10">10</a>].</p><p>The magnitude of the influence of cardiovascular disease on the risk of SCA is illustrated by several observations:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of SCA is increased 6- to 10-fold in the presence of clinically recognized heart disease, and two- to four-fold in the presence of coronary heart disease (CHD) risk factors [<a href="#rid8">8,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCD is the mechanism of death in over 60 percent of patients with known CHD [<a href="#rid5">5,12,13</a>]. In addition, SCA is the <strong>initial</strong> clinical manifestation of CHD in approximately 15 percent [<a href="#rid14">14</a>]. </p><p></p><p class="headingAnchor" id="H4"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>SCA usually occurs in people with some form of underlying structural heart disease, most notably CHD  (<a class="graphic graphic_table graphicRef62184" href="/z/d/graphic/62184.html" rel="external">table 1</a>). The etiologies of SCA are discussed in detail separately, but will be briefly reviewed here. (See  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Coronary heart disease</span><span class="headingEndMark"> — </span>The majority of SCAs have been attributed to CHD. Among patients with CHD, SCA can occur both during a transient episode of ischemia or<strong> </strong>an acute coronary syndrome (ACS) and in the setting of chronic, otherwise stable CHD (often such patients have had prior myocardial damage and scar that serves as a substrate for SCA) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p>The arrhythmic mechanisms and the implications for SCA survivors are different in these two settings. (See  <a class="medical medical_review" href="/z/d/html/973.html" rel="external">"Prognosis and outcomes following sudden cardiac arrest in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Other structural heart disease</span><span class="headingEndMark"> — </span>Other forms of structural heart disease, both acquired and hereditary, account for approximately 10 percent of cases of SCA. Examples of such disorders include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure and dilated cardiomyopathy of any etiology in which SCD is responsible for approximately one-third of deaths. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular hypertrophy due to hypertension or other causes. (See  <a class="medical medical_review" href="/z/d/html/966.html" rel="external">"Left ventricular hypertrophy and arrhythmia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrative cardiomyopathy (eg, cardiac sarcoid, cardiac amyloid). (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Management of arrhythmias and conduction system disease'</a> and  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis", section on 'Sudden death prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmogenic right ventricular cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/4929.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Pathogenesis and genetics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital coronary artery anomalies. (See  <a class="medical medical_review" href="/z/d/html/1536.html" rel="external">"Congenital and pediatric coronary artery abnormalities"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitral valve prolapse. (See  <a class="medical medical_review" href="/z/d/html/8162.html" rel="external">"Natural history of chronic mitral regurgitation caused by mitral valve prolapse and flail mitral leaflet"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Valvular heart disease (eg, aortic stenosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital heart disease (eg, tetralogy of Fallot).</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Absence of structural heart disease</span><span class="headingEndMark"> — </span>In different reports, approximately 10 to 12 percent of cases of SCA among subjects under age 45 without defined structural heart disease [<a href="#rid15">15,16</a>], while a lower value of about 5 percent has been described when older patients are included [<a href="#rid17">17,18</a>]. San Francisco County between February 2011 and March 2014 suggested greater than 40 percent of clinically-defined SCD was non-arrhythmic in origin, due to causes including occult overdose, neurologic disorders, infection, etc [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">"Approach to sudden cardiac arrest in the absence of apparent structural heart disease"</a>.)</p><p>SCA can occur due to:</p><p class="bulletIndent1"><span class="glyph">●</span>Brugada syndrome (See  <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">"Brugada syndrome: Clinical presentation, diagnosis, and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic VF, also called primary electrical disease (See  <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">"Approach to sudden cardiac arrest in the absence of apparent structural heart disease", section on 'Idiopathic VF'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital or acquired long QT syndrome  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 2</a>) (See  <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital short QT interval or syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial polymorphic ventricular tachycardia, also called "catecholaminergic polymorphic VT" (See  <a class="medical medical_review" href="/z/d/html/916.html" rel="external">"Catecholaminergic polymorphic ventricular tachycardia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial SCD of uncertain cause</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wolff-Parkinson-White syndrome (See  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Ventricular fibrillation and sudden death'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Acute triggers</span><span class="headingEndMark"> — </span>In addition to the presence of the underlying disorders of structural heart disease, superimposed triggers for SCA appear to play a major role. </p><p class="bulletIndent1"><span class="glyph">●</span>These include ischemia, electrolyte disturbances (particularly hypokalemia and hypomagnesemia), proarrhythmic effects of some antiarrhythmic drugs, autonomic nervous system activation, and psychosocial factors. (See  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest", section on 'Transient or reversible causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Commotio cordis – SCA can also result from commotio cordis in which VF is precipitated by direct trauma over precordium. (See  <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">"Approach to sudden cardiac arrest in the absence of apparent structural heart disease", section on 'Commotio cordis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circadian pattern – SCA has a circadian pattern with a reported peak during the waking hours of 7 to 11 am [<a href="#rid19">19-21</a>]. Among 5200 Framingham Heart Study participants over a 38-year period, 429 cases of SCD were 70 percent higher at 7 to 9 am than they were at other times of day or night [<a href="#rid21">21</a>]. A separate study of 1200 in- and out-of-hospital arrests in Pittsburgh showed the lowest risk of SCA was during early morning sleep hours, between 12 and 6 am [<a href="#rid22">22</a>]. The circadian pattern of SCD mirrors that of other cardiac issues (such as angina, heart failure, and other arrhythmias) that are also more common in the morning [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">The circadian pattern may result from pineal gland secretion of melatonin-stimulating hormone, resulting in increased melatonin levels and from a morning cortisol surge. Melatonin increases vagal tone, causing lower sympathetic tone and a slower heart rate at night. Melatonin levels are lower in morning (when natural light hits retina suppressing pineal activity) and hence vagal tone is lower. At the same time, the morning cortisol surge also increases as a result of increased sympathetic tone. </p><p></p><p class="headingAnchor" id="H116036026"><span class="h2">Warning symptoms</span><span class="headingEndMark"> — </span>"Warning" symptoms may precede the SCA event in a large number of patients, but symptoms may be unrecognized or minimized by patients, and subsequent ascertainment of symptoms is often limited, particularly in patients who do not survive the event. In addition, patients who have SCA and are resuscitated often have a retrograde amnesia and hence do not remember events or symptoms that may have been present. In a community-based study of 839 patients with SCA between 2002 and 2012 in whom symptom assessment could be ascertained (either from the surviving patient or from family members, witnesses at the scene of the event, or medical records from the four weeks leading up to the event), 430 patients (51 percent) were identified as having warning symptoms within four weeks preceding SCA [<a href="#rid24">24</a>]. Eighty percent of patients experienced symptoms at least one hour before SCA, with 34 percent having symptoms more than 24 hours before SCA. Chest pain (46 percent) and dyspnea (18 percent) were the most common symptoms, with women more likely to have experienced dyspnea than chest pain (31 versus 24 percent). Patients with symptoms concerning for cardiac disease, particularly new or unstable symptoms, should seek prompt medical care for potentially life-saving evaluation and treatment. (See  <a class="medical medical_review" href="/z/d/html/6832.html" rel="external">"Outpatient evaluation of the adult with chest pain", section on 'Cardiac conditions'</a> and  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p>As symptoms are nonspecific and may reflect benign conditions, and as these symptoms may not necessarily occur before all episodes of cardiac arrest (insensitive), their presence may not be of value in helping offset or prevent episodes. A causal or temporal relationship between symptoms and sudden death has not been established.</p><p class="headingAnchor" id="H9"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>A number of clinical characteristics and other factors are associated with an increased risk of SCA among persons without prior clinically recognized heart disease [<a href="#rid25">25-30</a>]. It should be noted that these risk factors are neither specific nor highly sensitive for SCA prediction. Most risk factors for CHD are also risk factors for SCA. These include dyslipidemia, hypertension, cigarette smoking, physical inactivity, obesity, diabetes mellitus, and a family history of premature CHD or myocardial infarction  (<a class="graphic graphic_figure graphicRef55353" href="/z/d/graphic/55353.html" rel="external">figure 3</a>) [<a href="#rid10">10,25-27,31,32</a>]. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Cigarette smoking</span><span class="headingEndMark"> — </span>Current cigarette smoking and the number of cigarettes smoked per day among current smokers are strongly related to the risk of SCA in patients with CHD. As an example, among 101,018 women followed for 30 years in the Nurses' Health Study, current smokers had a significantly greater risk of SCD than women who had never smoked (adjusted hazard ratio 2.44, 95% CI 1.80-3.31), and there was an increased risk even among those women who smoked 1 to 14 cigarettes per day (adjusted hazard ratio 1.84, 95% CI 1.16-2.92) [<a href="#rid33">33</a>]. For women in this study who stopped smoking, the risk of SCD declined over time in a linear fashion; these women had the same risk of SCD as never smokers 20 years after quitting [<a href="#rid33">33</a>].</p><p>Based upon the observations that the risk of SCA is particularly high among current smokers and declines rapidly after stopping smoking, smoking cessation should be viewed as a critical component of efforts to reduce the risk of SCA as well as a multitude of other complications. (See  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>The risk of SCA is transiently increased during and up to 30 minutes after strenuous exercise compared to other times [<a href="#rid27">27,34</a>]. However, the actual risk during any one episode of vigorous exercise is very low (1 per 1.51 million episodes of exercise) [<a href="#rid34">34</a>]. Furthermore, the magnitude of the transient increase in risk during acute exercise is lower among men who are regular exercisers compared with men for whom exercise is unusual [<a href="#rid27">27,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a>.)</p><p>The small transient increase in risk during exercise is <strong>outweighed</strong> by a reduction in the risk of SCA at other times [<a href="#rid25">25,35</a>]. Regular exercise is associated with a lower resting heart rate and increased heart rate variability, characteristics associated with a reduced risk of SCD. (See  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>One exception to the lower overall risk associated with intensive exercise occurs in patients with certain, often unrecognized underlying heart diseases. Examples include hypertrophic cardiomyopathy, anomalous coronary artery of wrong sinus origin, myocarditis, and arrhythmogenic right ventricular cardiomyopathy [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/986.html" rel="external">"Athletes: Overview of sudden cardiac death risk and sport participation"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Family history of SCA</span><span class="headingEndMark"> — </span>A family history of SCA, either alone or with myocardial infarction, is associated with a 1.5 to 1.8-fold increased risk of SCA [<a href="#rid26">26,32</a>]. The increase in risk is not explained by traditional risk factors that tend to aggregate in families, such as hypercholesterolemia, hypertension, diabetes mellitus, and obesity.</p><p>The magnitude of the increase in risk associated with the presence of a family history is modest compared to the two- to five-fold increase in risk associated with other modifiable risk factors such as physical inactivity and current cigarette smoking. Few studies have examined potential gene-environment interactions related to the risk of SCD. Nevertheless, it is likely that interactions of mutations or polymorphisms in specific genes and environmental factors influence this risk.</p><p class="headingAnchor" id="H399643099"><span class="h2">Diabetes</span><span class="headingEndMark"> — </span>Among patients with diabetes, type 1 diabetes was more strongly associated with SCA compared with type 2 diabetes and had less favorable outcomes following resuscitation. In a community-based case-control study, 2771 people with SCA were compared with 8313 demographic-matched controls [<a href="#rid38">38</a>]. </p><p>The following findings were noted: </p><p class="bulletIndent1"><span class="glyph">●</span>People with diabetes were associated with 1.5 times higher odds of SCA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among those with diabetes, the odds of having SCA were 2.41 times higher in type 1 than in type 2 diabetes (95% CI 1.53-3.80; p&lt;0.001). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>People with SCA with type 1 diabetes were more likely to have an unwitnessed arrest, less likely to receive resuscitation, and less likely to survive compared with those with type 2 diabetes. </p><p></p><p class="headingAnchor" id="H13"><span class="h2">Serum CRP</span><span class="headingEndMark"> — </span>Chronic inflammation, as manifested in part by higher serum concentrations of C-reactive protein (CRP), has been implicated as a risk factor for a variety of cardiovascular diseases (including acute coronary syndromes and stroke). Elevated serum CRP is also associated with an increased risk of SCA [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Excess alcohol intake</span><span class="headingEndMark"> — </span>Moderate alcohol intake (eg, one to two drinks per day and avoidance of binge drinking) may decrease the risk of SCD [<a href="#rid40">40,41</a>]. In comparison, heavy alcohol consumption (four to six or more drinks per day) or binge drinking <strong>increases</strong> the risk for SCD. This may be a result of alcohol withdrawal that occurs with heavy alcohol use or binge drinking (which has been termed the "holiday heart syndrome"). Alcohol withdrawal is associated with an elevation of sympathetic neural activity and circulating catecholamines.</p><p>Each specific type of alcoholic drink (eg, beer, wine, spirits) may have different associations with SCD. In a study from the United Kingdom Biobank, 408,712 middle-aged participants were followed for a median of 12 years for the development of SCD [<a href="#rid40">40</a>]. There were 2044 SCD events. Total alcohol consumption had a U-shaped association with SCD, with the lowest-risk group reporting &lt;26 drinks per week. Consumption of greater amounts of beer, cider, and spirits were associated with increasing SCD risk, whereas increasing wine intake was associated with reduced risk. </p><p>The association of alcohol with other cardiovascular disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Psychosocial factors</span><span class="headingEndMark"> — </span>Clinical observations have suggested a possible relation between acutely stressful situations and the risk of SCA. Major disasters, such as earthquakes and war, result in a rapid transient increase in the rate of SCA in populations [<a href="#rid28">28,29</a>]. The level of educational attainment and social support from others may alter the risk associated with stressful life events. (See  <a class="medical medical_review" href="/z/d/html/4851.html" rel="external">"Psychosocial factors in sudden cardiac arrest"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Caffeine</span><span class="headingEndMark"> — </span>Excessive caffeine intake has been investigated as a potential risk factor for SCA [<a href="#rid42">42</a>]. In the limited data available, no significant association between caffeine intake and SCA have been found.</p><p class="headingAnchor" id="H17"><span class="h2">Fatty acids</span><span class="headingEndMark"> — </span>Elevated plasma nonesterified fatty acid (free fatty acid) concentrations were associated with ventricular arrhythmias and SCD after a myocardial infarction [<a href="#rid43">43</a>]. However, nonesterified fatty acids were not associated with SCD in the Cardiovascular Health Study, a population-based cohort of older adults [<a href="#rid44">44</a>]. In addition, in a population-based case-control study among persons without prior clinically recognized heart disease, SCA cases had higher concentrations of trans isomers of linoleic acid in red blood cell membranes [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/4555.html" rel="external">"Dietary fat"</a>.)</p><p>In contrast, a higher dietary intake and higher levels of long-chain n-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in plasma and the red blood cell membrane are associated with a <strong>lower</strong> risk of SCD [<a href="#rid30">30,46-48</a>]. (See <a class="local">'Fish intake and fish oil'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The acute management of cardiac arrest is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13838.html" rel="external">"Initial assessment and management of the adult post-cardiac arrest patient"</a>.)</p><p>Management issues for survivors of SCA include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Identification and treatment of acute reversible causes, especially myocardial ischemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for structural heart disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients without obvious arrhythmic triggers or cardiac structural abnormalities, an evaluation for primary electrical diseases</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic and psychologic assessment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In selected patients with a suspected or confirmed heritable syndrome, evaluation of family members</p><p></p><p>These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/970.html" rel="external">"Cardiac evaluation of the survivor of sudden cardiac arrest"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">PRIMARY PREVENTION</span><span class="headingEndMark"> — </span>The optimal approach to the primary prevention of SCA varies depending on the patient group, as discussed in the sections below. </p><p class="headingAnchor" id="H20"><span class="h2">General population</span><span class="headingEndMark"> — </span>There are two approaches to reduce the risk of SCA in the general population:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening and risk stratification to identify high-risk individuals who may benefit from specific interventions (eg, stress testing, screening ECGs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interventions that may be expected to reduce SCA risk in any individual (eg, smoking cessation or other lifestyle modifications). Such interventions generally target the underlying disorders that predispose to SCA.</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Screening and risk stratification</span><span class="headingEndMark"> — </span>Among populations already known to be at an elevated risk of SCA (eg, patients with a prior myocardial infarction), further risk stratification with a variety of tests can identify subgroups that benefit from specific therapies, such as primary prevention with an ICD, particularly those with an ischemic cardiomyopathy and left ventricular ejection fraction &lt;35 percent. (See <a class="local">'Ischemic heart disease'</a> below and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p>However, in the general population without known cardiovascular disease, there is no evidence that routine screening with any test (eg, 12-lead electrocardiography, exercise stress testing, or Holter monitoring) effectively identifies populations at an increased risk of SCA.</p><p>With regard to risk stratification of the general population, we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening for risk factors for cardiovascular disease according to standard guidelines. (See  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.) The USPSTF clinical practice guideline for screening for high blood pressure, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.uspreventiveservicestaskforce.org%2Fuspstf%2Frecommendation-topics%2Ftools-and-resources-for-better-preventive-care&amp;token=gU9WNl81NfxUW5PaMO19B42aXfNh0%2FLL9q2zAVmEgoGSHQUtiYHAfwRDOAU5wYccq4zSybuWXRZCzTCIJUuWCq4XmhMv3cgOxBxKqUbaRGZ0zq8CGq77FkJGvNZkLGjcrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=963" target="_blank">www.uspreventiveservicestaskforce.org/</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for CHD as appropriate in selected patients, according to standard guidelines. (See  <a class="medical medical_review" href="/z/d/html/1519.html" rel="external">"Screening for coronary heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine additional testing for the purpose of SCA risk stratification is not recommended.</p><p></p><p>An issue that merits special consideration is the pre-participation evaluation of athletes. This is a complex issue and there are conflicting opinions regarding whether to screen and, if so, the appropriate nature of a screening evaluation, such as with an electrocardiogram or echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/960.html" rel="external">"Screening to prevent sudden cardiac death in competitive athletes"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Risk factor reduction</span><span class="headingEndMark"> — </span>Many of the traditional risk factors associated with the development of CHD are also associated with SCA. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>Thus, management of these risk factors may reduce the incidence of SCA in the general public. Such interventions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Effective treatment of hypercholesterolemia</p><p class="bulletIndent1"><span class="glyph">●</span>Effective treatment of hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Adoption of a heart-healthy diet</p><p class="bulletIndent1"><span class="glyph">●</span>Regular exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking cessation</p><p class="bulletIndent1"><span class="glyph">●</span>Moderation of alcohol consumption</p><p class="bulletIndent1"><span class="glyph">●</span>Effective treatment of diabetes</p><p></p><p>These interventions are generally in agreement with guidelines published in 2001 by a task force of the European Society of Cardiology [<a href="#rid49">49</a>].</p><p>There is no definitive evidence that risk factor reduction in the general population lowers the rate of SCA. However, a number of studies have demonstrated that interventions to treat risk factors can lower total cardiovascular and coronary mortality. Since the majority of CHD mortality is due to SCD, these results suggest that interventions to reduce risk factors will reduce SCA rates as well. (See  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>As an example, a multifactorial, controlled, randomized trial from the Belgian component of the World Health Organization evaluated the effect of efforts aimed at reducing serum cholesterol (via dietary changes), increasing physical activity, and controlling smoking, hypertension, and weight (in those who were overweight) on risk factors and mortality [<a href="#rid50">50</a>]. Compared to the control group, the intervention group had significant reductions in the incidence of CHD and coronary mortality.</p><p class="headingAnchor" id="H23"><span class="h3">Moderate alcohol intake</span><span class="headingEndMark"> — </span>Excess alcohol intake increases the risk of SCA, while light-to-moderate alcohol consumption (ie, ≤2 drinks per day) is associated with a lower risk of coronary heart disease and cardiovascular mortality [<a href="#rid41">41,51</a>]. (See <a class="local">'Excess alcohol intake'</a> above.)</p><p>It is reasonable to expect that moderate alcohol intake will also reduce SCA. This effect was documented by the Physicians Health Study, which evaluated 21,537 men who were free of known cardiovascular disease [<a href="#rid41">41</a>]. Compared to men who rarely or never drank, those who had two to four drinks per week or five to six drinks per week had a significantly reduced risk for SCD (relative risks 0.40 and 0.21, respectively); the risk approached unity at ≥2 drinks per day. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Regular exercise</span><span class="headingEndMark"> — </span>There are no data from long-term exercise intervention trials among apparently healthy persons that focus upon major disease end points. Nevertheless, regular exercise should be encouraged for the primary prevention of CHD and SCA. Although there is a small transient increase in risk during and shortly after strenuous exercise, there is an overall reduction in SCD among exercisers compared with sedentary men [<a href="#rid25">25,27,35,52</a>]. It is unclear if more exercise (higher intensity or longer duration) is better than less (non-strenuous physical activity, such as walking for exercise 30 minutes most days). (See <a class="local">'Exercise'</a> above and  <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a> and  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>Patients should be advised to pay attention to potential symptoms of CHD, even if they have engaged in regular exercise without limitations for an extended period of time. In addition, patients with known heart disease should be encouraged to engage in regular exercise in a supervised setting such as a cardiac rehabilitation program. (See  <a class="medical medical_review" href="/z/d/html/1477.html" rel="external">"Cardiac rehabilitation programs"</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Fish intake and fish oil</span><span class="headingEndMark"> — </span>In observational studies of populations at low cardiovascular risk, greater dietary fatty fish intake was associated with lower cardiac mortality [<a href="#rid30">30,47,48,53,54</a>]. This benefit is due in part to a reduced risk of SCD. Based upon these results, subsequent randomized trials evaluated the benefit of fish oil supplements in various high-risk populations [<a href="#rid55">55,56</a>]. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5365.html" rel="external">"Fish oil: Physiologic effects and administration"</a>.)</p><p>For most individuals, there is little evidence that the pharmacologic doses of n-3 polyunsaturated fatty acids found in fish oil supplements (approximately 10 to 20 times the nutritional dose from fish) provide more protection than the intake of one to two servings of fatty fish (eg, salmon) per week. The pharmacologic use of fish oils supplements should be restricted to patients with refractory hypertriglyceridemia and, in such patients, the periodic monitoring of apolipoprotein B levels is recommended. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Treatment goals'</a>.) </p><p class="headingAnchor" id="H26"><span class="h2">Ischemic heart disease</span><span class="headingEndMark"> — </span>Patients who have ischemic heart disease, particularly those who have had an MI, are at an increased risk of SCA. However, among post-MI patients, this risk varies significantly according to a number of factors.</p><p>The approach to the prevention of SCA in such patients includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Standard medical therapies. Both beta blockers and ACE inhibitors (or angiotensin II receptor blockers) reduce overall mortality after an MI and are routinely administered. These agents also lower the incidence of SCD. However, the benefit may be limited to three years post MI. Beta blockers post-MI are useful for a longer period of time in patients with post-MI heart failure or ongoing chronic angina. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF", section on 'Guideline-directed medical therapy'</a> and  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk stratification to identify those patients at the highest risk of SCA. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ICD implantation in selected patients, ie, those with an ischemic cardiomyopathy and LVEF &lt;35 percent. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Heart failure and cardiomyopathy</span><span class="headingEndMark"> — </span>Patients with heart failure and left ventricular systolic dysfunction, regardless of the etiology, are at an increased risk of SCA. Primary prevention with an ICD is recommended in selected patients with either ischemic or nonischemic cardiomyopathy, although recent studies have shown less if any benefit of an ICD in those with a nonischemic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF", section on 'Use of an ICD'</a>.)</p><p>In addition, as with patients with CHD, standard medical therapies for HF (beta blockers, ACE inhibitors or angiotensin II receptor blockers, and aldosterone inhibitors such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>) may lower the risk of SCA. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy", section on 'Heart failure therapy'</a>.)</p><p class="headingAnchor" id="H582724591"><span class="h2">Inherited arrythmia syndromes</span><span class="headingEndMark"> — </span>Patients with one of the congenital disorders associated with an increased risk of SCA (eg, Brugada syndrome, congenital long QT syndrome, Wolff-Parkinson-White syndrome) are at increased risk for SCA<em>. </em>(See  <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">"Brugada syndrome: Clinical presentation, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis"</a>.)<em> </em></p><p class="headingAnchor" id="H28"><span class="h2">Counseling patients and families</span><span class="headingEndMark"> — </span>Given the mounting evidence related to the primary prevention of SCA, it now is clear that primary care clinicians can influence the occurrence of these events. As discussed above, there are clinical recommendations for those at risk of SCA that are likely to reduce risk. (See <a class="local">'Risk factor reduction'</a> above.)</p><p class="headingAnchor" id="H29"><span class="h1">SECONDARY PREVENTION</span></p><p class="headingAnchor" id="H30"><span class="h2">ICD therapy</span><span class="headingEndMark"> — </span>An implantable cardioverter-defibrillator (ICD) is the preferred therapeutic modality in most survivors of SCA. The ICD does not prevent the recurrence of malignant ventricular arrhythmias, but it effectively terminates these arrhythmias when they do recur. The role of the ICD in survivors of SCA is presented separately. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p>ICD patients who have frequent arrhythmia recurrences and device discharges may benefit from adjunctive therapies, such as antiarrhythmic drugs or catheter ablation. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Antiarrhythmic drugs'</a> and  <a class="medical medical_review" href="/z/d/html/972.html" rel="external">"Pharmacologic therapy in survivors of sudden cardiac arrest", section on 'Treatment of breakthrough arrhythmias'</a> and  <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Radiofrequency catheter ablation'</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Other antiarrhythmic therapies</span><span class="headingEndMark"> — </span>Antiarrhythmic drugs are less effective than an ICD for secondary prevention of SCD. Thus, their use in this setting is limited to the adjunctive role described above, or in patients who do not want or are not candidates for an ICD (eg, due to marked comorbidities or end-stage heart failure that make death likely). Patients in whom ventricular arrhythmias result in recurrent shocks despite antiarrhythmic medications may be candidates for catheter ablation in an effort to reduce the arrhythmic burden. (See  <a class="medical medical_review" href="/z/d/html/972.html" rel="external">"Pharmacologic therapy in survivors of sudden cardiac arrest"</a> and  <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Radiofrequency catheter ablation'</a>.)</p><p class="headingAnchor" id="H18020743"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82912.html" rel="external">"Patient education: Sudden cardiac arrest (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>The following summary and recommendations address general issues related to sudden cardiac arrest (SCA) and sudden cardiac death (SCD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background –</strong> SCA and SCD refer to the sudden cessation of cardiac activity with hemodynamic collapse. Events that are successfully treated with patient survival are referred to as SCA, while those that lead to death are referred to as SCD. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– SCD is common, accounting for up to 15 percent of total mortality in industrialized countries, based upon review of death certificate data. Smaller prospective studies, however, have suggested a lower incidence. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology </strong>– SCA is most commonly due to ventricular tachyarrhythmias (ie, ventricular fibrillation or ventricular tachycardia). The risk of such arrhythmic events is increased in patients with coronary heart disease or other forms of structural heart disease. In patients with hearts that appear structurally normal, relatively uncommon primary arrhythmia syndromes can cause SCA. (See <a class="local">'Etiology'</a> above and  <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">"Approach to sudden cardiac arrest in the absence of apparent structural heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– The risk factors for SCA are similar to those for coronary heart disease. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The acute management of SCA involves standard cardiopulmonary resuscitation protocols. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prevention </strong>–<strong> </strong>A heart-healthy lifestyle, including habitual physical activity, a heart-healthy diet, and abstinence or cessation of cigarette smoking, is recommended for the primary prevention of SCD. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General population without known cardiac disease:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Apart from standard screening and management of risk factors for CHD (eg, measurement of lipids, BP, and glucose), in patients without known cardiac disease we recommend no additional screening tests or treatment for the purpose of primary prevention of SCD (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'General population'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Preparticipation screening of athletes for the purpose of preventing SCD is a unique issue that is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/960.html" rel="external">"Screening to prevent sudden cardiac death in competitive athletes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with known cardiac disease (eg, prior MI, cardiomyopathy, or heart failure) are at an increased risk of SCA. (See <a class="local">'Ischemic heart disease'</a> above and <a class="local">'Heart failure and cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent2">The approach to the primary prevention of SCA in such patients includes the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Standard medical therapies that lower the incidence of SCA. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy", section on 'Heart failure therapy'</a> and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF", section on 'Guideline-directed medical therapy'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testing for the purpose of SCA risk stratification in selected subgroups. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ICD implantation in selected patients. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy", section on 'Prevention of SCD'</a> and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of survivors of SCA includes the identification and treatment of acute reversible causes, evaluation for structural heart disease and/or primary electrical diseases, neurologic and psychologic assessment, and evaluation of family members in selected cases. (See  <a class="medical medical_review" href="/z/d/html/970.html" rel="external">"Cardiac evaluation of the survivor of sudden cardiac arrest"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary prevention of SCD, usually with an ICD, is appropriate for most SCA survivors. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="headingAnchor" id="H1064028663"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David Siscovick, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology), Buxton AE, Calkins H, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). Circulation 2006; 114:2534.</a></li><li><a class="nounderline abstract_t">Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis 1994; 37:39.</a></li><li><a class="nounderline abstract_t">Siscovick DS. Challenges in cardiac arrest research: data collection to assess outcomes. Ann Emerg Med 1993; 22:92.</a></li><li><a class="nounderline abstract_t">Tseng ZH, Olgin JE, Vittinghoff E, et al. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation 2018; 137:2689.</a></li><li><a class="nounderline abstract_t">Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158.</a></li><li><a class="nounderline abstract_t">Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation 2022; 145:e153.</a></li><li><a class="nounderline abstract_t">Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004; 44:1268.</a></li><li><a class="nounderline abstract_t">Rea TD, Pearce RM, Raghunathan TE, et al. Incidence of out-of-hospital cardiac arrest. Am J Cardiol 2004; 93:1455.</a></li><li><a class="nounderline abstract_t">Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136:205.</a></li><li><a class="nounderline abstract_t">Bertoia ML, Allison MA, Manson JE, et al. Risk factors for sudden cardiac death in post-menopausal women. J Am Coll Cardiol 2012; 60:2674.</a></li><li><a class="nounderline abstract_t">Kuller LH. Sudden death--definition and epidemiologic considerations. Prog Cardiovasc Dis 1980; 23:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death--United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51:123.</a></li><li><a class="nounderline abstract_t">Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989; 79:756.</a></li><li><a class="nounderline abstract_t">Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975; 51:606.</a></li><li><a class="nounderline abstract_t">Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68:1388.</a></li><li><a class="nounderline abstract_t">Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985; 87:476.</a></li><li><a class="nounderline abstract_t">Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102:649.</a></li><li><a class="nounderline abstract_t">Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95:265.</a></li><li><a class="nounderline abstract_t">Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75:131.</a></li><li><a class="nounderline abstract_t">Willich SN. Epidemiologic studies demonstrating increased morning incidence of sudden cardiac death. Am J Cardiol 1990; 66:15G.</a></li><li><a class="nounderline abstract_t">Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987; 60:801.</a></li><li><a class="nounderline abstract_t">Tang Y, Tertulien T, Bhonsale A, et al. Comparison of Circadian Variation for In-Hospital Versus Out-of-Hospital Sudden Cardiac Arrest Survivors. Am J Cardiol 2021; 160:1.</a></li><li><a class="nounderline abstract_t">Fabbian F, Bhatia S, De Giorgi A, et al. Circadian Periodicity of Ischemic Heart Disease: A Systematic Review of the Literature. Heart Fail Clin 2017; 13:673.</a></li><li><a class="nounderline abstract_t">Marijon E, Uy-Evanado A, Dumas F, et al. Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest. Ann Intern Med 2016; 164:23.</a></li><li><a class="nounderline abstract_t">Siscovick DS, Weiss NS, Hallstrom AP, et al. Physical activity and primary cardiac arrest. JAMA 1982; 248:3113.</a></li><li><a class="nounderline abstract_t">Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998; 97:155.</a></li><li><a class="nounderline abstract_t">Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 1984; 311:874.</a></li><li><a class="nounderline abstract_t">Trichopoulos D, Katsouyanni K, Zavitsanos X, et al. Psychological stress and fatal heart attack: the Athens (1981) earthquake natural experiment. Lancet 1983; 1:441.</a></li><li><a class="nounderline abstract_t">Kark JD, Goldman S, Epstein L. Iraqi missile attacks on Israel. The association of mortality with a life-threatening stressor. JAMA 1995; 273:1208.</a></li><li><a class="nounderline abstract_t">Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274:1363.</a></li><li><a class="nounderline abstract_t">Kannel WB, Thomas HE Jr. Sudden coronary death: the Framingham Study. Ann N Y Acad Sci 1982; 382:3.</a></li><li><a class="nounderline abstract_t">Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99:1978.</a></li><li><a class="nounderline abstract_t">Sandhu RK, Jimenez MC, Chiuve SE, et al. Smoking, smoking cessation, and risk of sudden cardiac death in women. Circ Arrhythm Electrophysiol 2012; 5:1091.</a></li><li><a class="nounderline abstract_t">Albert CM, Mittleman MA, Chae CU, et al. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 2000; 343:1355.</a></li><li><a class="nounderline abstract_t">Lemaitre RN, Siscovick DS, Raghunathan TE, et al. Leisure-time physical activity and the risk of primary cardiac arrest. Arch Intern Med 1999; 159:686.</a></li><li><a class="nounderline abstract_t">Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.</a></li><li><a class="nounderline abstract_t">Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.</a></li><li><a class="nounderline abstract_t">Norby FL, Reinier K, Uy-Evanado A, et al. Sudden Cardiac Death in Patients With Type 1 Versus Type 2 Diabetes. Mayo Clin Proc 2022; 97:2271.</a></li><li><a class="nounderline abstract_t">Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595.</a></li><li><a class="nounderline abstract_t">Tu SJ, Gallagher C, Elliott AD, et al. Alcohol consumption and risk of ventricular arrhythmias and sudden cardiac death: An observational study of 408,712 individuals. Heart Rhythm 2022; 19:177.</a></li><li><a class="nounderline abstract_t">Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. Circulation 1999; 100:944.</a></li><li><a class="nounderline abstract_t">Weinmann S, Siscovick DS, Raghunathan TE, et al. Caffeine intake in relation to the risk of primary cardiac arrest. Epidemiology 1997; 8:505.</a></li><li><a class="nounderline abstract_t">Jouven X, Charles MA, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001; 104:756.</a></li><li><a class="nounderline abstract_t">Djoussé L, Biggs ML, Ix JH, et al. Nonesterified fatty acids and risk of sudden cardiac death in older adults. Circ Arrhythm Electrophysiol 2012; 5:273.</a></li><li><a class="nounderline abstract_t">Lemaitre RN, King IB, Raghunathan TE, et al. Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation 2002; 105:697.</a></li><li><a class="nounderline abstract_t">Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161:2185.</a></li><li><a class="nounderline abstract_t">Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002; 346:1113.</a></li><li><a class="nounderline abstract_t">Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336:1046.</a></li><li><a class="nounderline abstract_t">Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374.</a></li><li><a class="nounderline abstract_t">De Backer G, Kornitzer M, Dramaix M, et al. The Belgian Heart Disease Prevention Project: 10-year mortality follow-up. Eur Heart J 1988; 9:238.</a></li><li><a class="nounderline abstract_t">Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. Br Heart J 1992; 68:443.</a></li><li><a class="nounderline abstract_t">Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation 1999; 99:963.</a></li><li><a class="nounderline abstract_t">Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312:1205.</a></li><li><a class="nounderline abstract_t">Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279:23.</a></li><li><a class="nounderline abstract_t">Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.</a></li><li><a class="nounderline abstract_t">Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447.</a></li></ol></div><div id="topicVersionRevision">Topic 963 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130345" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022985" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of sudden coronary death: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8424623" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Challenges in cardiac arrest research: data collection to assess outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29915095" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684624" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sudden cardiac death in the United States, 1989 to 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35078371" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364331" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of out-of-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704680" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sudden coronary death in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177296" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for sudden cardiac death in post-menopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6994170" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sudden death--definition and epidemiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898927" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : State-specific mortality from sudden cardiac death--United States, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924409" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sudden coronary death in the United States: 1980-1985.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/123182" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Precursors of sudden coronary death. Factors related to the incidence of sudden death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951130" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sudden unexpected death in persons less than 40 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4038935" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathologic features of sudden death in children, adolescents, and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931805" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sudden cardiac death with apparently normal heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994445" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3791599" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Circadian variation in the frequency of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2239706" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemiologic studies demonstrating increased morning incidence of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3661393" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34583813" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of Circadian Variation for In-Hospital Versus Out-of-Hospital Sudden Cardiac Arrest Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865776" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circadian Periodicity of Ischemic Heart Disease: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720493" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7143686" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Physical activity and primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445167" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Family history as a risk factor for primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6472399" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The incidence of primary cardiac arrest during vigorous exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6131167" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psychological stress and fatal heart attack: the Athens (1981) earthquake natural experiment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Iraqi missile attacks on Israel. The association of mortality with a life-threatening stressor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563561" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7044245" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sudden coronary death: the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209001" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predicting sudden death in the population: the Paris Prospective Study I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233741" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Smoking, smoking cessation, and risk of sudden cardiac death in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11070099" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Triggering of sudden death from cardiac causes by vigorous exertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218747" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Leisure-time physical activity and the risk of primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12651044" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691102" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Screening for hypertrophic cardiomyopathy in young athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272817" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sudden Cardiac Death in Patients With Type 1 Versus Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045163" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Alcohol consumption and risk of ventricular arrhythmias and sudden cardiac death: An observational study of 408,712 individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468525" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270951" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Caffeine intake in relation to the risk of primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502698" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281952" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonesterified fatty acids and risk of sudden cardiac death in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839624" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cell membrane trans-fatty acids and the risk of primary cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575974" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948270" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Blood levels of long-chain n-3 fatty acids and the risk of sudden death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091800" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fish consumption and the 30-year risk of fatal myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11482917" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Task Force on Sudden Cardiac Death of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289930" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Belgian Heart Disease Prevention Project: 10-year mortality follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1467026" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Alcohol and sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027821" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Exercise as cardiovascular therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3990713" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The inverse relation between fish consumption and 20-year mortality from coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424039" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fish consumption and risk of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997274" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10465168" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
